Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

EY Names Proscia CEO David West as Entrepreneur Of The Year® 2021 Greater Philadelphia Award Finalist

By Author Proscia | June 22, 2021

West recognized for leading digital and computational pathology company in modernizing 150-year-old standard of cancer research and diagnosis

PHILADELPHIA – June 22, 2021 – Ernst & Young LLP (EY US) announced that David West, CEO of Proscia®, was named an Entrepreneur Of The Year® 2021 Greater Philadelphia Award finalist. Now in its 35th year, the Entrepreneur Of The Year program honors unstoppable business leaders whose ambition, ingenuity, and courage in the face of adversity help catapult us from the now to next and beyond.

West was selected by a panel of independent judges based on six criteria: entrepreneurial leadership; talent management; degree of difficulty; financial performance; societal impact and building a values-based company; and originality, innovation, and future plans. Since its launch, the program has expanded to recognize business leaders in more than 145 cities in over 60 countries around the world.

During West’s tenure as CEO, Proscia has emerged as a market leader in digital and computational pathology, transforming the 150-year-old standard of cancer research and diagnosis from microscope to image with its Concentriq® platform and portfolio of AI applications. The company has amassed a customer base of laboratory titans and digital pathology pioneers as well as more than half of the top twenty pharmaceutical organizations. This includes the Joint Pathology Center, the premiere pathology reference center for the U.S. government, and LabPON, the first laboratory in the world to reach 100% digital pathology diagnosis. Since co-founding Proscia in 2014, West has built a global team of 85 industry and domain experts and has secured $35M in fundraising from Scale Venture Partners and Hitachi Ventures among other top investors.

“It’s a great honor to be recognized among such inspiring leaders as a finalist for the Entrepreneur Of The Year Award,” said David West, CEO of Proscia. “I started Proscia to change the way the world practices pathology, an aim that would not be possible to achieve without the tireless commitment of our team. We thank EY for recognizing Proscia’s success in helping to accelerate breakthroughs and improve patient outcomes and applaud its support of entrepreneurship around the world.”

Award winners will be announced during a special virtual celebration on July 27, 2021 and will become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world.

About Entrepreneur Of The Year®
Entrepreneur Of The Year® is the world’s most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. National Overall winners go on to compete for the EY World Entrepreneur Of The Year™ title.

About Proscia
Proscia is a software company that is changing the way the world practices pathology to transform research and diagnosis for diseases like cancer. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. For more information, visit

Our website uses cookies. By using this site, you agree to its use of cookies.